Neurocrine Biosciences (NBIX) EBT (QoQ) (2010 - 2026)
Neurocrine Biosciences (NBIX) EBT (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Alkermes | 8.07 Bn | 7.41 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.28% |
| Mar 31, 2026 | 3.09% |
| Dec 31, 2025 | -17.96% |
| Sep 30, 2025 | 82.95% |
| Jun 30, 2025 | 985.03% |
| Mar 31, 2025 | -90.96% |
| Dec 31, 2024 | -14.56% |
| Sep 30, 2024 | 93.00% |
| Jun 30, 2024 | 185.80% |
| Mar 31, 2024 | -82.59% |
| Dec 31, 2023 | 71.45% |
| Sep 30, 2023 | -4.93% |
| Jun 30, 2023 | 217.72% |
| Mar 31, 2023 | -187.62% |
| Dec 31, 2022 | 20.43% |
| Sep 30, 2022 | 520.17% |
| Jun 30, 2022 | -208.88% |
| Mar 31, 2022 | 255.07% |
| Dec 31, 2021 | -145.25% |
| Sep 30, 2021 | -46.96% |